Physician profile
Devendra Bhachawat
NPI 1053338731
$7,465.03
in general payments reported to CMS, 2019-2025
58 companies · $2,094 in 2025
The $2,094 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $179 · 2021: $275 · 2022: $1,027 · 2023: $934 · 2024: $1,918 · 2025: $2,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,801 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,800.92 |
| Education | $144.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $940.76 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $604.23 | 2019-2025 | Opdivo, Eliquis |
| Astrazeneca Pharmaceuticals LP | $545.23 | 2019-2025 | Calquence, Imfinzi, Tagrisso |
| Pfizer INC. | $430.30 | 2019-2025 | |
| Janssen Biotech, INC. | $410.15 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Genzyme Corporation | $309.03 | 2019-2025 | |
| Pharmaessentia USA Corporation | $292.55 | 2022-2025 | Besremi |
| Sobi, INC | $253.63 | 2022-2025 | |
| Blueprint Medicines Corporation | $248.97 | 2024-2025 | Ayvakit |
| Astellas Pharma US INC | $221.09 | 2024-2025 | Vyloy, Xospata, Xtandi |
| Merck Sharp & Dohme LLC | $196.37 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $194.49 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $179.23 | 2022-2025 | Iclusig, Ninlaro, Fruzaqla |
| Array Biopharma INC | $152.32 | 2020-2025 | Xalkori, Mektovi, Braftovi |
| Alexion Pharmaceuticals, INC. | $136.20 | 2019-2025 | Soliris, Ultomiris |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $132.56 | 2022-2025 | Reblozyl |
| Glaxosmithkline, LLC. | $119.34 | 2023-2025 | Ojjaara, Shingrix |
| Aveo Pharmaceuticals, INC. | $112.16 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.77 | 2019-2020 | |
| Genentech USA, INC. | $94.99 | 2024-2025 | Tecentriq, Columvi, Polivy |
| Daiichi Sankyo INC. | $94.29 | 2024-2025 | Enhertu, Datroway |
| Exelixis INC. | $93.79 | 2024 | Cabometyx |
| Recordati_rare_diseases_inc. | $92.95 | 2024-2025 | Sylvant, Enjaymo |
| Janssen Pharmaceuticals, INC | $91.95 | 2022-2024 | Xarelto |
| Genmab U.S., INC. | $83.70 | 2025 | Epkinly |
| Global Blood Therapeutics, INC. | $82.04 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $77.42 | 2024-2025 | Orgovyx |
| Agios Pharmaceuticals, INC. | $71.79 | 2024-2025 | Pyrukynd |
| Eisai INC. | $70.94 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $69.99 | 2024 | |
| Deciphera Pharmaceuticals INC. | $68.67 | 2024-2025 | Qinlock, Romvimza |
| Ipsen Biopharmaceuticals, INC | $64.44 | 2024-2025 | Onivyde |
| Rigel Pharmaceuticals, INC. | $62.88 | 2019-2024 | Tavalisse, Rezlidhia |
| Jazz Pharmaceuticals INC. | $62.13 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.91 | 2023-2024 | |
| Shield Therapeutics INC | $49.17 | 2023 | Accrufer |
| Taiho Oncology, INC. | $48.86 | 2022-2024 | |
| Amgen INC. | $44.00 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $42.46 | 2024-2025 | Vivimusta, Danziten |
| Karyopharm Therapeutics INC. | $38.02 | 2024-2025 | Xpovio |
| Tersera Therapeutics LLC | $35.48 | 2025 | Zoladex |
| Octapharma USA, INC. | $35.45 | 2023 | Octagam Immune Globulin (Human) |
| Adc Therapeutics America, INC. | $33.83 | 2024-2025 | |
| Lilly USA, LLC | $33.42 | 2019-2024 | Jaypirca, Verzenio |
| Emd Serono, INC. | $31.35 | 2025 | |
| Legend Biotech USA INC. | $27.42 | 2025 | Carvykti |
| Geron Corporation | $26.29 | 2025 | Rytelo |
| Abbvie INC. | $26.00 | 2024 | |
| Syndax Pharmaceuticals, INC. | $23.63 | 2025 | |
| Fennec Pharmaceuticals, INC. | $23.09 | 2024 | Pedmark |
| Pharmacosmos Therapeutics INC. | $18.19 | 2024 | Cosela |
| Gilead Sciences, INC. | $17.98 | 2019 | |
| Tesaro, INC. | $16.59 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $16.43 | 2019 | |
| Medtronic USA, INC. | $16.34 | 2019 | |
| Dova Pharmaceuticals | $14.60 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.31 | 2020 | |
| Amag Pharmaceuticals, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devendra Bhachawat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.